Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer
The purpose of this research is to determine the effectiveness of CGC-11047 in subjects with metastatic hormone refractory prostate cancer as measured by changes in PSA.
Prostate Cancer
DRUG: CGC-11047
Efficacy, 8 weeks
Safety, Throughout and for 28 days post drug
The purpose of this research is to determine the effectiveness of CGC-11047 in subjects with metastatic hormone refractory prostate cancer as measured by changes in PSA.